CD274 and neoplasm: Additionally, PD-L1+ EVs produced by cancer cells are a prominent mechanism of immunotherapy resistance by acting as off-target decoys for αPD-1 monoclonal antibodies that are used to reinvigorate anti-tumour T cell immunity [209].